BACKGROUND: Occult lymph node (LN) metastases are clinically relevant and confer a worse prognosis in non-small-cell lung cancer (NSCLC) patients. Current staging methods are unable to identify patients with poor outcome. Their detection requires both a more sensitive and specific technique. We aimed to assess the role of messenger RNA expression in pathologically negative LNs (pN0) of stage I NSCLC patients as markers of occult micrometastases and to correlate the results with local or distant tumor recurrence and survival. PATIENTS AND METHODS: Potential molecular markers were evaluated in 344 LNs and 38 tumors by quantitative real-time RT-PCR. Only CEACAM5 and PLUNC showed high expression in lung tumor tissue and null expression in RNA from benign LNs. RESULTS: Thirteen per cent of the LNs were positive for CEACAM5 and 16% for PLUNC. Eight of 38 NSCLC patients had positive expression in pN2 nodes by CEACAM5 and/or PLUNC and disease-free survival (P=0.028) and overall survival time was significantly worse in these patients compared with those with negative expression (P=0.0083). CONCLUSIONS: Quantitative real-time RT-PCR of CEACAM5 and PLUNC can estimate the presence of micrometastatic cells in LNs with greater precision than current staging method used for assessing tumor recurrence risk.
BACKGROUND: Occult lymph node (LN) metastases are clinically relevant and confer a worse prognosis in non-small-cell lung cancer (NSCLC) patients. Current staging methods are unable to identify patients with poor outcome. Their detection requires both a more sensitive and specific technique. We aimed to assess the role of messenger RNA expression in pathologically negative LNs (pN0) of stage I NSCLCpatients as markers of occult micrometastases and to correlate the results with local or distant tumor recurrence and survival. PATIENTS AND METHODS: Potential molecular markers were evaluated in 344 LNs and 38 tumors by quantitative real-time RT-PCR. Only CEACAM5 and PLUNC showed high expression in lung tumor tissue and null expression in RNA from benign LNs. RESULTS: Thirteen per cent of the LNs were positive for CEACAM5 and 16% for PLUNC. Eight of 38 NSCLCpatients had positive expression in pN2 nodes by CEACAM5 and/or PLUNC and disease-free survival (P=0.028) and overall survival time was significantly worse in these patients compared with those with negative expression (P=0.0083). CONCLUSIONS: Quantitative real-time RT-PCR of CEACAM5 and PLUNC can estimate the presence of micrometastatic cells in LNs with greater precision than current staging method used for assessing tumor recurrence risk.
Authors: J M Galbis-Caravajal; A Lafuente-Sanchis; M Estors-Guerrero; N Martinez-Hernández; C Fuster-Diana; A Cremades; Á Zúñiga Journal: Clin Transl Oncol Date: 2017-01-27 Impact factor: 3.405
Authors: Chukwumere E Nwogu; Sai Yendamuri; Wei Tan; Eric Kannisto; Paul Bogner; Carl Morrison; Richard Cheney; Elisabeth Dexter; Anthony Picone; Mark Hennon; Alan Hutson; Mary Reid; Alex Adjei; Todd L Demmy Journal: J Thorac Cardiovasc Surg Date: 2013-03 Impact factor: 5.209
Authors: Laura Millares; Mireia Serra; Felipe Andreo; Jose Sanz-Santos; Concepción Montón; Carles Grimau; Miguel Gallego; Laia Setó; Neus Combalia; Mariona Llatjos; Rosa Escoda; Eva Castellà; Eduard Monsó Journal: Clin Exp Metastasis Date: 2015-06-29 Impact factor: 5.150
Authors: Gabriele Gamerith; Johannes Rainer; Julia M Huber; Hubert Hackl; Zlatko Trajanoski; Stefan Koeck; Edith Lorenz; Johann Kern; Reinhard Kofler; Jens M Kelm; Heinz Zwierzina; Arno Amann Journal: Oncotarget Date: 2017-11-06